Interferon beta-1a sc at 25 years: a mainstay in the treatment of multiple sclerosis over the period of one generation

Uwe Klaus Zettl; Paulus Stefan Rommer; Orhan Aktas; Torsten Wagner; Joachim Richter; Patrick Oschmann; Lukas Cepek; Birte Elias-Hamp; Klaus Gehring; Andrew Chan; Michael Hecker

doi:10.1080/1744666X.2023.2248391

Interferon beta-1a sc at 25 years: a mainstay in the treatment of multiple sclerosis over the period of one generation

Uwe Klaus Zettl, Paulus Stefan Rommer, Orhan Aktas, Torsten Wagner, Joachim Richter, Patrick Oschmann, Lukas Cepek, Birte Elias-Hamp, Klaus Gehring, Andrew Chan, Michael Hecker

Research output: Contribution to journal › Review article › peer-review

2 Scopus citations

Abstract

Introduction: Interferon beta (IFN beta) preparations are an established group of drugs used for immunomodulation in patients with multiple sclerosis (MS). Subcutaneously (sc) applied interferon beta-1a (IFN beta-1a sc) has been in continuous clinical use for 25 years as a disease-modifying treatment. Areas covered: Based on data published since 2018, we discuss recent insights from analyses of the pivotal trial PRISMS and its long-term extension as well as from newer randomized studies with IFN beta-1a sc as the reference treatment, the use of IFN beta-1a sc across the patient life span and as a bridging therapy, recent data regarding the mechanisms of action, and potential benefits of IFN beta-1a sc regarding vaccine responses. Expert opinion: IFN beta-1a sc paved the way to effective immunomodulatory treatment of MS, enabled meaningful insights into the disease process, and remains a valid therapeutic option in selected vulnerable MS patient groups.

Original language	English
Pages (from-to)	1343-1359
Number of pages	17
Journal	Expert Review of Clinical Immunology
Volume	19
Issue number	11
DOIs	https://doi.org/10.1080/1744666X.2023.2248391
State	Published - 2023
Externally published	Yes

Keywords

25 years
Interferon beta-1a
disease-modifying therapy
generation
long-term efficacy
long-term safety
mechanisms of action
multiple sclerosis

Access to Document

10.1080/1744666X.2023.2248391

Cite this

Zettl, U. K., Rommer, P. S., Aktas, O., Wagner, T., Richter, J., Oschmann, P., Cepek, L., Elias-Hamp, B., Gehring, K., Chan, A., & Hecker, M. (2023). Interferon beta-1a sc at 25 years: a mainstay in the treatment of multiple sclerosis over the period of one generation. Expert Review of Clinical Immunology, 19(11), 1343-1359. https://doi.org/10.1080/1744666X.2023.2248391

@article{27fe0fb5c4934d60b34e09a28ac3ba69,

title = "Interferon beta-1a sc at 25 years: a mainstay in the treatment of multiple sclerosis over the period of one generation",

abstract = "Introduction: Interferon beta (IFN beta) preparations are an established group of drugs used for immunomodulation in patients with multiple sclerosis (MS). Subcutaneously (sc) applied interferon beta-1a (IFN beta-1a sc) has been in continuous clinical use for 25 years as a disease-modifying treatment. Areas covered: Based on data published since 2018, we discuss recent insights from analyses of the pivotal trial PRISMS and its long-term extension as well as from newer randomized studies with IFN beta-1a sc as the reference treatment, the use of IFN beta-1a sc across the patient life span and as a bridging therapy, recent data regarding the mechanisms of action, and potential benefits of IFN beta-1a sc regarding vaccine responses. Expert opinion: IFN beta-1a sc paved the way to effective immunomodulatory treatment of MS, enabled meaningful insights into the disease process, and remains a valid therapeutic option in selected vulnerable MS patient groups.",

keywords = "25 years, Interferon beta-1a, disease-modifying therapy, generation, long-term efficacy, long-term safety, mechanisms of action, multiple sclerosis",

author = "Zettl, {Uwe Klaus} and Rommer, {Paulus Stefan} and Orhan Aktas and Torsten Wagner and Joachim Richter and Patrick Oschmann and Lukas Cepek and Birte Elias-Hamp and Klaus Gehring and Andrew Chan and Michael Hecker",

note = "Publisher Copyright: {\textcopyright} 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.",

year = "2023",

doi = "10.1080/1744666X.2023.2248391",

language = "English",

volume = "19",

pages = "1343--1359",

journal = "Expert Review of Clinical Immunology",

issn = "1744-666X",

publisher = "Taylor and Francis Ltd.",

number = "11",

}

TY - JOUR

T1 - Interferon beta-1a sc at 25 years

T2 - a mainstay in the treatment of multiple sclerosis over the period of one generation

AU - Zettl, Uwe Klaus

AU - Rommer, Paulus Stefan

AU - Aktas, Orhan

AU - Wagner, Torsten

AU - Richter, Joachim

AU - Oschmann, Patrick

AU - Cepek, Lukas

AU - Elias-Hamp, Birte

AU - Gehring, Klaus

AU - Chan, Andrew

AU - Hecker, Michael

PY - 2023

Y1 - 2023

N2 - Introduction: Interferon beta (IFN beta) preparations are an established group of drugs used for immunomodulation in patients with multiple sclerosis (MS). Subcutaneously (sc) applied interferon beta-1a (IFN beta-1a sc) has been in continuous clinical use for 25 years as a disease-modifying treatment. Areas covered: Based on data published since 2018, we discuss recent insights from analyses of the pivotal trial PRISMS and its long-term extension as well as from newer randomized studies with IFN beta-1a sc as the reference treatment, the use of IFN beta-1a sc across the patient life span and as a bridging therapy, recent data regarding the mechanisms of action, and potential benefits of IFN beta-1a sc regarding vaccine responses. Expert opinion: IFN beta-1a sc paved the way to effective immunomodulatory treatment of MS, enabled meaningful insights into the disease process, and remains a valid therapeutic option in selected vulnerable MS patient groups.

AB - Introduction: Interferon beta (IFN beta) preparations are an established group of drugs used for immunomodulation in patients with multiple sclerosis (MS). Subcutaneously (sc) applied interferon beta-1a (IFN beta-1a sc) has been in continuous clinical use for 25 years as a disease-modifying treatment. Areas covered: Based on data published since 2018, we discuss recent insights from analyses of the pivotal trial PRISMS and its long-term extension as well as from newer randomized studies with IFN beta-1a sc as the reference treatment, the use of IFN beta-1a sc across the patient life span and as a bridging therapy, recent data regarding the mechanisms of action, and potential benefits of IFN beta-1a sc regarding vaccine responses. Expert opinion: IFN beta-1a sc paved the way to effective immunomodulatory treatment of MS, enabled meaningful insights into the disease process, and remains a valid therapeutic option in selected vulnerable MS patient groups.

KW - 25 years

KW - Interferon beta-1a

KW - disease-modifying therapy

KW - generation

KW - long-term efficacy

KW - long-term safety

KW - mechanisms of action

KW - multiple sclerosis

UR - http://www.scopus.com/inward/record.url?scp=85170666640&partnerID=8YFLogxK

U2 - 10.1080/1744666X.2023.2248391

DO - 10.1080/1744666X.2023.2248391

M3 - Review article

C2 - 37694381

AN - SCOPUS:85170666640

SN - 1744-666X

VL - 19

SP - 1343

EP - 1359

JO - Expert Review of Clinical Immunology

JF - Expert Review of Clinical Immunology

IS - 11

ER -

Interferon beta-1a sc at 25 years: a mainstay in the treatment of multiple sclerosis over the period of one generation

Abstract

Keywords

Access to Document

Fingerprint

Cite this